FDA Recalls Dexamethasone Sodium Phosphate Injection Due to Impurity Specification Failure
Eugia US LLC recalls 70,125 vials of Dexamethasone Sodium Phosphate injection due to failed impurity specifications. Testing found sulfonic acid adduct of dexamethasone phosphate exceeded allowed limits.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II classification indicates possible serious adverse health consequences. Although no illnesses or injuries have been reported, the manufacturing defect involving elevated chemical impurities in an injectable medication constitutes a risk-of-harm product where injury has not yet been reported.
Plain-English summary
Dexamethasone Sodium Phosphate injection USP (120mg per 30mL) has been recalled due to failed impurity specifications. Quality testing identified that sulfonic acid adduct of dexamethasone phosphate levels exceeded specification limits in affected batches.
The recall involves 70,125 vials distributed nationwide by AuroMedics Pharma LLC. Affected lot numbers are 3DS23001, 3DS23004, 3DS23009, and 3DS23011. The product was manufactured by Eugia US LLC with NDC 55150-239-30.
This is a Class II FDA recall. Healthcare providers and patients who have received this medication should contact their healthcare provider or pharmacist for guidance regarding any vials that may have been dispensed or administered.
The recalled product
- Product
- DEXAMETHASONE SODIUM PHOSPHATE (DEXAMETHASONE SODIUM PHOSPHATE)
- Brand
- DEXAMETHASONE SODIUM PHOSPHATE
- Manufacturer
- Eugia US LLC
- Category
- Drug — Injectable Corticosteroid
- Affected units
- 70,125
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot#: 3DS23001
- 3DS23004
- Exp 6/30/2024
- 3DS23009
- 3DS23011
- Exp 7/31/2024
UPCs (2)
- 0355150239306
- 0355150237012
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DEXAMETHASONE SODIUM PHOSPHATE
- HighDexamethasone injection failed impurity specifications at product expiry testing
FDA (Drugs) · 2026-03-25
- LowWest-Ward Recalls Dexamethasone Sodium Phosphate Injection Due to Impurities
FDA (Drugs) · 2017-11-29
- LowWest-Ward Recalls Dexamethasone Sodium Phosphate Injection Due to Impurity
FDA (Drugs) · 2017-11-29
Same manufacturer · Eugia US LLC
See all →- ModerateEugia lidocaine vial label wrap covers the barcode
FDA (Drugs) · 2026-06-10
- ModerateGentamicin Injection Pediatric Vials Recalled for Failed Stability Tests
FDA (Drugs) · 2025-06-25
- ModerateTirofiban Hydrochloride Injection recalled for out-of-specification test results
FDA (Drugs) · 2025-05-07
- ModerateTirofiban Injection Recalled for Out-of-Specification Test Results
FDA (Drugs) · 2025-05-07
- ModerateTestosterone Cypionate Injection Recalled for Insoluble Crystals
FDA (Drugs) · 2025-04-23
Same hazard · chemical impurity
See all →- SevereErythromycin 500 mg Tablets Recalled for Impurity Above Limits
FDA (Drugs) · 2026-05-27
- HighDuloxetine Delayed-Release Capsules Recalled for Manufacturing Impurity Above Safe Limits
FDA (Drugs) · 2025-01-15
- HighDuloxetine antidepressant recall for chemical impurity above FDA limit
FDA (Drugs) · 2025-01-01
- HighMorphine Sulfate Extended-Release Tablets Recalled for Impurities and Degradation
FDA (Drugs) · 2024-11-13
- HighCinacalcet Tablets Recalled Due to Nitrosamine Impurity
FDA (Drugs) · 2024-11-06